Moderna stock heads into the open after a 1.9 percent drop
Published on 09/17/2026 at 04:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna stock closed at USD 143.77 on the Nasdaq on September 15, 2026, down about 1.9 percent from the prior session’s close of USD 146.69 per Nasdaq data cited in recent market summaries. The shares traded between USD 141.16 and USD 148.70 over the course of the session, with volume around 8.4 million shares, leaving the stock within a 52-week range of USD 22.28 to USD 176.66.
September 15, 2026 in numbers
Moderna Inc. (ISIN US60770K1034, Nasdaq: MRNA) saw renewed selling pressure on September 15, 2026 as the stock settled at USD 143.77 on the Nasdaq, roughly 2.0 percent below the previous close of USD 146.69, according to a corporate-news summary that drew on Nasdaq data. As Ad-hoc-news reported on September 16, 2026, intraday levels ranged from a low of USD 141.16 to a high of USD 148.70, with turnover of about 8.4 million shares, highlighting active trading as mid-September volatility persisted.
The same report noted that the close left Moderna shares below their recent 50-day range high of USD 174.38 but comfortably above the 52-week low near USD 22.28, underlining how the stock has rebounded strongly over the past year while remaining sensitive to news around its pipeline and regulatory backdrop. According to MarketBeat, the broader Nasdaq Composite slipped 0.8 percent to close at 25,981.57 on September 16, 2026, so Moderna’s decline on September 15, 2026 roughly matched the technology-heavy index’s weak tone in the same midweek period.
Today’s focus around Fed and sector moves
Looking ahead to today, Moderna is likely to trade in the context of recent moves in United States equities and health care names after the Federal Reserve shifted toward a more restrictive stance. As Zacks reported in its stock market news for September 16, 2026, the Dow Jones Industrial Average fell 1.2 percent and the Nasdaq Composite slipped 0.8 percent as investors reacted to the Fed’s latest signal on interest rates, a backdrop that can influence valuations for growth-oriented biotechnology stocks such as Moderna.
Sector performance also provides context for today’s session. A United States market wrap from Sina Finance on September 17, 2026 highlighted that many pharmaceutical and biotechnology stocks, including Moderna, posted gains of slightly more than 1 percent in the latest completed trading session as investors rotated within the health care segment after the Fed decision. Earnings calendar data compiled by Zacks indicate that Moderna’s next quarterly earnings release is expected on November 5, 2026 for the September 2026 quarter, with consensus pointing to earnings per share around USD -1.36, so investors may increasingly position for that update in the coming weeks even though no company-specific event is scheduled for today.
